Cardiovascular disease
Why SONG-HD Cardiovascular Disease?
Cardiovascular disease (CVD) is the leading cause of premature mortality and morbidity in patients on haemodialysis (HD). Compared to the general population, patients on HD have a 5 – 30 fold increased risk of CVD, which accounts for about 50% of all-cause mortality. The aim of SONG-HD Cardiovascular disease is to develop a core outcome measure for cardiovascular disease to be included in all trials in patients requiring haemodialysis.
SONG-HD Cardiovascular Disease Expert Working Group
David Wheeler (Chair) | University College London, United Kingdom
Adeera Levin | University of British Columbia, Canada
Angela Wang | The University of Hong Kong, Hong Kong
Christoph Wanner |Universitätsklinikum Würzburg, Germany
Chuck Herzog |Hennepin County Medical Center, United States
Faiez Zannad | Université de Lorraine, France
Giovanni Strippoli | University of Bari, Italy
Jolanta Malyszko | Medical University of Bialystik, Poland
Marcello Tonelli | University of Calgary, Canada
Meg Jardine | The George Institute for Global Health, Australia
Michael Rocco | Wake Forest University, United States
Tazeen Jafar | Duke – National University Singapore, Singapore
Vera Krane |Universitätsklinikum Würzburg, Germany
Will Herrington | Oxford University, United Kingdom
Emma O’Lone (Project Coordinator) | The University of Sydney, Australia
Project updates
1. Review of outcome measures for cardiovascular disease
We conducted a comprehensive systematic review to identify, describe and evaluate all outcome measures that have been used for cardiovascular disease in clinical trials involving patients on haemodialysis.
2. Survey
An international online survey was launched to identify what cardiovascular outcomes are most important to patients, caregivers and health professional.
3. SONG-HD Cardiovascular Disease Consensus workshop
The SONG-HD Cardiovascular Disease Consensus Workshop was held 2nd November 2017 in New Orleans. A total of 61 attendees (including eight patients and family members) shared their experiences and expertise relevant to establishing a core outcome measure for cardiovascular disease to be reported in all trials in people on haemodialysis. A draft report will be circulated to all attendees and investigators early 2018.
Attendees* and contributors: David Wheeler (Chair)*, Emma O’Lone (Project Coordinator)*, Adeera Levin*, Christoph Wanner*, Chuck Herzog*, Faiez Zannad, Giovanni Strippoli*, Jolanta Malyszko*, Marcello Tonelli, Meg Jardine*, Mike Rocco*, Tazeen Jafar, Vera Krane, Will Herrington*, Jonathan Craig*, Allison Tong*, Angela Wang*, Brenda Hemmelgarn, Braden Manns*, John Gill, Peter Tugwell, Roberto Pecoits-Filho*, Sally Crowe, Tess Harris*, Wim Van Biesen, Wolfgang Winkelmayer*, Myra Kleinpeter*, N.Kevin Krane, Andrea Viecelli*, Angela Ju*, Jenny Shen, Yeoungjee Cho*, Talia Gutman*, Amelie Bernier-Jean*, Laura James*, Benedicte Sautenet, Lorraine Hamiwka*, Amy Kelly, Ankit Sharma, Ayano Kelly, Armando Teixeira-Pinto, Barbara Gillespie, Camilla Hanson, Daniel Sumpton, Karine Manera, Kim Linh Van, Martin Howell, Nicole Evangelidis, Richard McGee, Sarah Bernays, Alan Jardine*, Amino Bello*, Andrew Narva, Ann O’Hare, Benedicte Stengel*, Brigitte Schiller*, Carol Pollock, Charmaine Lok, Claudio Ronco, David Harris, David Johnson*, Denis Fouque, Devika Nair, Elena Bavlovlenkov*, Fergus Caskey*, Francesca Tentori, Franz Schaefer, Geoffrey Block*, Hai An Phan*, Hiddo Lambers*, Janet Wittes, Jennifer Flythe, John Kellum, Juan Jesus Carreo Roia, Julie Ishida, Kevan Polkinghorne, Kimberly Smith, Lawrence Agodoa, Magdalena Madero*, Mahesh Krishnan, Marinella Ruospo*, Mark Marshall, Mark Unruh*, Maurice Laville*, Nisha Bansal*, Patrick Mark*, Patric Parfrey, Patrick Rossignol, P.J. Blankestijn*, Prabir Roy-Chaudhury*, Priti Patel, Rachel Perlman*, Rainer Oberbauer, Rajiv Agarwal*, Rajnish Mehrotra*, Ron Gansevoort, Sreedhar Mandayam, Stephen Seliger*, Tariq Shafi*, Thomas Hiemstra*, Vanita Jassal*, Vikram Aggarwal, Vivekanand Jha, Vlado Perkovic*, Amanda Simplice*, David White*, David Rosenbloom, Denise Eilers*, Herbert Alexander*, Kevin Fowler, Monica Hamm, Nieltje Gedney, Pam Duquette, William Walther Jr, Yvonne Landry*, Gennifer Landry*, Caroline Wilkie*
4. Expert Roundtable Meeting – myocardial infarction (heart attack)
Myocardial infarction (heart attack) was identified as SONG-HD core CVD outcome. A Roundtable Meeting was convened in Washington DC (November 2019) with patients, nephrologists, cardiologists and regulators to discuss which definition of myocardial infarction should be used in trials in patients on haemodialysis.
Attendees* and contributors: Chuck Herzog (Chair)*, David C Wheeler (Co-Chair), Jonathan C Craig (Co-Chair)*, Emma O’Lone (Project Coordinator)*, Fred Apple, James Burton*, Fergus Caskey*, David Charytan, Christopher Defillippi*, Derek Forfang*, Karen Hicks*, Vivek Jha*, Ken Mahaffey*, Patrick Mark*, Nicki Scholes-Robertson*, Patrick Rossignol, Kimberly Smith*, Aliza Thompson*, Allison Tong*, David White*, Andrea Viecelli*, Angela Wang*, Wolfgang Winkelmayer